[go: up one dir, main page]

BG102836A - Бензазепинови производни, лекарствени средства, които ги съдържат, и тяхното приложение за получаването на лекарства - Google Patents

Бензазепинови производни, лекарствени средства, които ги съдържат, и тяхното приложение за получаването на лекарства

Info

Publication number
BG102836A
BG102836A BG102836A BG10283698A BG102836A BG 102836 A BG102836 A BG 102836A BG 102836 A BG102836 A BG 102836A BG 10283698 A BG10283698 A BG 10283698A BG 102836 A BG102836 A BG 102836A
Authority
BG
Bulgaria
Prior art keywords
forms containing
medicaments
preparation
application
new
Prior art date
Application number
BG102836A
Other languages
English (en)
Other versions
BG64560B1 (bg
Inventor
Laszlo Czollner
Johannes Froehlich
Ulrich Jordis
Kuenburg Bernhard
Original Assignee
Sanochemia Pharmazeutika Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanochemia Pharmazeutika Aktiengesellschaft filed Critical Sanochemia Pharmazeutika Aktiengesellschaft
Publication of BG102836A publication Critical patent/BG102836A/bg
Publication of BG64560B1 publication Critical patent/BG64560B1/bg

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Изобретението се отнася до нови бензазепини, по-специално на бензофуро[3a,3,2,ef][2], с обща формула I и нови съединения с обща формула III Изобретението се отнася също и до лекарствени средства, съдържащи съединенията с формула I и/илиIII, които могат да се използват за лечение на болестта на Алцхаймер и сродни състояния на деменция, както и на синдрома на Langdon-Down. </P>
BG102836A 1996-04-19 1998-10-12 Бензазепинови производни, лекарствени средства, които ги съдържат, и тяхното приложение за получаването на лекарства BG64560B1 (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0071696A AT403803B (de) 1996-04-19 1996-04-19 Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln

Publications (2)

Publication Number Publication Date
BG102836A true BG102836A (bg) 1999-09-30
BG64560B1 BG64560B1 (bg) 2005-07-29

Family

ID=3497932

Family Applications (1)

Application Number Title Priority Date Filing Date
BG102836A BG64560B1 (bg) 1996-04-19 1998-10-12 Бензазепинови производни, лекарствени средства, които ги съдържат, и тяхното приложение за получаването на лекарства

Country Status (12)

Country Link
US (2) US6638925B2 (bg)
EP (2) EP1757608A1 (bg)
AT (1) AT403803B (bg)
AU (1) AU2498597A (bg)
BG (1) BG64560B1 (bg)
CZ (1) CZ300211B6 (bg)
IS (1) IS4839A (bg)
NO (1) NO324211B1 (bg)
PL (2) PL190032B1 (bg)
RO (1) RO120136B1 (bg)
TW (1) TWI224595B (bg)
WO (1) WO1997040049A1 (bg)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT403803B (de) * 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
AU1430099A (en) * 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
WO2000066586A1 (en) * 1999-05-04 2000-11-09 Neurosearch A/S Heteroaryl diazabicycloalkanes, their preparation and use
CA2368966A1 (en) * 2000-03-31 2001-10-11 Sanochemia Pharmazeutika Aktiengesellschaft New derivatives and analogues of galanthamine
KR100768245B1 (ko) * 2000-03-31 2007-10-17 자노케미아 파마조이티카 악티엔게젤샤프트 신규한 갈란타민 유도체 및 유사체
CA2409644A1 (en) * 2000-05-25 2001-11-29 Targacept, Inc. Heteroaryldiazabicycloalkanes as nicotinic cholinergic receptor ligands
US6440970B1 (en) * 2000-05-25 2002-08-27 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2001265831B9 (en) * 2000-07-04 2006-08-31 Neurosearch A/S Aryl and heteroaryl diazabicycloalkanes, their preparation and use
GEP20053617B (en) * 2000-10-19 2005-09-26 Pfizer Prod Inc Bridged Piperazine Derivatives
EP1340499A4 (en) * 2000-12-07 2006-05-03 Astellas Pharma Inc MEANS FOR REINFORCING THE NOOTROPIC EFFECT
MXPA03010612A (es) * 2001-05-22 2004-04-02 Neurogen Corp Ligandos receptores de la hormona concentradora de melanina: analogos de 1-bencil-4-aril piperazina substiruidos.
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
JP4721386B2 (ja) * 2001-07-10 2011-07-13 第一三共株式会社 新規ガランタミン類縁体
DE10134038A1 (de) * 2001-07-12 2003-02-06 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Therapie der Nikotinabhängigkeit
ES2355157T3 (es) * 2002-07-05 2011-03-23 Targacept, Inc. Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
AU2003254016A1 (en) 2002-07-19 2004-02-09 Catholic Healthcare West Methods and compositions relating to chimeric nicotinic receptor subunits
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
JPWO2005027968A1 (ja) * 2003-09-19 2007-11-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ダウン症候群治療剤
AT414125B (de) * 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
ATE451368T1 (de) * 2003-10-15 2009-12-15 Targacept Inc Azabicyclische verbindungen zur linderung von schmerzen und zur behandlung von erkrankungen des zentralen nervensystems
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
JP2007538085A (ja) * 2004-05-17 2007-12-27 アカディア ファーマシューティカルズ インコーポレイティド アンドロゲン受容体モジュレーターおよびそれを用いて疾患を治療する方法
US20070004679A1 (en) * 2004-05-17 2007-01-04 Nathalie Schlienger Androgen receptor modulators and methods of treating disease using the same
US20050261278A1 (en) * 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
EP1802601A1 (en) * 2004-09-20 2007-07-04 Targacept, Inc. Azaspiroalkene and azapiroalkane compounds with nicotinic cholinergic receptor activity
CA2585781A1 (en) 2004-11-03 2006-12-28 Iris Molecular Diagnostics, Inc. Homogeneous analyte detection
CN103091485A (zh) 2004-11-03 2013-05-08 艾瑞斯国际有限公司 用于亲和分离的微泡
US7459469B2 (en) * 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
ITMI20042413A1 (it) * 2004-12-17 2005-03-17 Indena Spa Processo per la preparazione di galantamina bromidrato
WO2006072818A2 (en) * 2005-01-04 2006-07-13 Emcure Pharmaceuticals Limited Process for preparation of galanthamine
US20060173037A1 (en) * 2005-01-10 2006-08-03 Nathalie Schlienger Aminophenyl derivatives as selective androgen receptor modulators
EP1836202B1 (en) * 2005-01-10 2016-12-21 Acadia Pharmaceuticals Inc. Aminophenyl derivatives as selective androgen receptor modulators
US20100168081A1 (en) * 2005-08-11 2010-07-01 Adriana Di Polo Galantamine as a neuroprotective drug for retinal ganglion cells
WO2007024814A1 (en) * 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
US20070213318A1 (en) * 2006-03-07 2007-09-13 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20090253654A1 (en) * 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
JP2009519933A (ja) 2005-12-14 2009-05-21 アムゲン インコーポレイティッド ジアザ複素環式スルホンアミド誘導体およびそれらの使用法
US8672732B2 (en) * 2006-01-19 2014-03-18 Schneider Electric It Corporation Cooling system and method
CN100384850C (zh) * 2006-04-14 2008-04-30 浙江大学 加兰他敏衍生物及制备方法和用途
EP2133337A1 (en) * 2006-05-09 2009-12-16 AstraZeneca AB Salt forms of (2S)-(4E)-N-Methyl-5-[(5-Isopropoxy)pyridin-3-yl]-4-penten-2-amine
TWI389889B (zh) * 2006-05-09 2013-03-21 Targacept Inc (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型
PT2041088E (pt) 2006-06-28 2014-03-26 Amgen Inc Inibidores do transportador-1 da glicina
TW200829244A (en) * 2006-09-15 2008-07-16 Astrazeneca Ab Therapeutic combinations 482
US20100028447A1 (en) * 2007-01-22 2010-02-04 Targacept, Inc. Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs
JP2010535237A (ja) * 2007-07-31 2010-11-18 ターガセプト・インコーポレイテッド (2s)−(4e)−n−メチル−5−(3−(5−イソプロポキシピリジン)イル)−4−ペンテン−2−アミンの経皮投与
JP5022494B2 (ja) * 2007-10-01 2012-09-12 コメンティス,インコーポレーテッド アルツハイマー病治療用のα7ニコチン性アセチルコリン受容体リガンドとしてのキヌクリジン−4−イルメチル1H−インドール−3−カルボキシレート誘導体
CA2721007C (en) 2008-04-14 2014-04-29 Galantos Pharma Gmbh Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
MX2012006484A (es) 2009-12-07 2012-08-01 Targacept Inc 3,6-diazabiciclo [3.1.1] heptanos como ligandos de receptores nicotinicos neuronales de acetilcolina.
WO2011146009A1 (en) 2010-05-20 2011-11-24 Targacept Inc. New process for the preparation of aryl substituted olefinic amines
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
CN104447767B (zh) * 2013-09-24 2018-08-03 连云港金康医药科技有限公司 氮杂双环[3,2,1]辛烷衍生物及其应用
EP3166940A4 (en) 2014-07-11 2018-04-25 Alpharmagen, LLC Quinuclidine compounds for modulating alpha7 -nicotinic acetylcholine receptor activity
WO2017189834A1 (en) * 2016-04-29 2017-11-02 New Mexico Tech Research Foundation Methods for treatment of resistant cancer
CN118908968A (zh) * 2024-10-09 2024-11-08 威胜生物医药(苏州)股份有限公司 一种加兰他敏中间体衍生物及其催化氧化制备方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3947445A (en) * 1974-05-09 1976-03-30 Stanford Research Institute Diazabicyclooctanes and diazabicycloheptanes
US4663318A (en) * 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
ATE411026T1 (de) 1987-05-04 2008-10-15 Bonnie Davis Mittel zur behandlung der alzheimer-krankheit
GB8800694D0 (en) 1988-01-13 1988-02-10 Pfizer Ltd Antiarrhythmic agents
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
US4954502A (en) * 1988-06-10 1990-09-04 Bristol-Myers Squibb Company 1-indolyalkyl-4-(substituted-pyridinyl)piperazines
CA2012681A1 (en) 1989-03-31 1990-09-30 Masayasu Okuhira Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
US5036153A (en) 1989-05-11 1991-07-30 Braish Tamim F Preparation of 2,5-diazabicyclo[2.2.1]heptanes and intermediates
US4994460A (en) 1989-06-01 1991-02-19 Bristol-Myers Squibb Co. Agents for treatment of brain ischemia
DK0507861T3 (bg) 1989-12-28 1997-03-03 Upjohn Co
HU213097B (en) 1991-05-14 1997-02-28 Egyt Gyogyszervegyeszeti Gyar Process for producing phenylpiperazines
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
US6323196B1 (en) * 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US5428159A (en) * 1994-04-08 1995-06-27 Ciba-Geigy Corporation Method of manufacture of (-)-galanthamine in high yield and purity substantially free of epigalanthamine
AU695352B2 (en) * 1994-10-21 1998-08-13 Sanochemia Pharmazeutika Ag Process for producing derivatives of 4a,5,9,10,11,12,-hexahydro-6h-benzofuro{3a,3,2-ef}{2} benzazepine
US6407229B1 (en) 1994-10-21 2002-06-18 Sanochemia Pharmazeutika Ag Processes for the preparation of derivatives of 4a,5,9,10,11,12-hexahydro-6H-benzofuro-[3a,3,2-ef][2] benzazapine
AT401058B (de) 1994-10-21 1996-06-25 Waldheim Pharmazeutika Gmbh Verfahren zum herstellen von derivaten des 4a,5, 9,10,11,12,-hexahydro-6h-benzofuro(3a,-3,2-ef) (2)benzazepins
GB9519268D0 (en) 1995-09-21 1995-11-22 Chiroscience Ltd Preparation of alkaloids
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
AU1430099A (en) 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln

Also Published As

Publication number Publication date
IS4839A (is) 1998-08-28
US20040067974A1 (en) 2004-04-08
CZ332498A3 (cs) 1999-05-12
EP0897387A1 (de) 1999-02-24
US6638925B2 (en) 2003-10-28
NO324211B1 (no) 2007-09-10
US7101890B2 (en) 2006-09-05
AT403803B (de) 1998-05-25
BG64560B1 (bg) 2005-07-29
AU2498597A (en) 1997-11-12
WO1997040049A1 (de) 1997-10-30
PL190032B1 (pl) 2005-10-31
PL329411A1 (en) 1999-03-29
US20030092700A1 (en) 2003-05-15
CZ300211B6 (cs) 2009-03-18
TWI224595B (en) 2004-12-01
RO120136B1 (ro) 2005-09-30
EP1757608A1 (de) 2007-02-28
PL189834B1 (pl) 2005-09-30
ATA71696A (de) 1997-10-15
NO984852D0 (no) 1998-10-16
NO984852L (no) 1998-11-16

Similar Documents

Publication Publication Date Title
BG102836A (bg) Бензазепинови производни, лекарствени средства, които ги съдържат, и тяхното приложение за получаването на лекарства
MY121047A (en) Bicyclo [2.2.1] heptanes and related compounds
UA66801C2 (uk) Триазоло[4,5-d]піримідинові сполуки, спосіб їх одержання (варіанти), фармацевтична композиція на їх основі та спосіб лікування порушень агрегації тромбоцитів
BG103417A (bg) Кондензирани бициклични производни на пиримидина
UA66825C2 (uk) Азаполіциклічні сполуки, конденсовані з арилом, фармацевтична композиція, спосіб лікування та спосіб зниження нікотинової залежності
BR9811022A (pt) Composto, composição farmacêutica, e, processo para preparação de um composto
BG104812A (bg) Нови дихидропиримидини
BR9713400A (pt) Processos e compostos para inibir liberação de peptìdeo beta-amilóide e/ou sua sìntese.
MX9605023A (es) Compuestos substituidos de imidazolidin-2,4-diona como substancias farmaceuticamente activas.
YU11501A (sh) Derivati 4,4,-biarilpiperidina sa aktivnošću na receptor opijata
AP9701041A0 (en) Pyridylpyrrole compounds.
YU79103A (sh) Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao antagonisti mglur2 i receptora
CA2270177A1 (en) Transdermal administration of ment
CA2262566A1 (en) Benzamidine derivatives and the use thereof as medicaments with ltb4-antagonistic effect
IL143105A0 (en) Fused polycyclic heterocyclic compounds and pharmaceutical compositions containing the same
WO1987004430A3 (en) Fused benzazepines
ATE272648T1 (de) Glycokonjugate von 20(s)-camptothecin
MY120550A (en) Substituted 1,2,3,4,5,6-hexahydro-2,6-methano-3-benzazocin-10-ols, processes for preparing them and their use as pharmaceutical compositions.
CA2372040A1 (en) Imidazodiazepine derivative
ATE251162T1 (de) Triazolo(4,5-d)pyrimidin-verbindungen
CA2344686A1 (en) High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
BG106002A (bg) Метод за получаване на пестицидни междинни съединения
WO1999058490A3 (en) Novel aryl-hydro naphthalenal kanamines
WO1999048851A3 (en) Processes for preparing intermediates
BG103196A (bg) Кристален фармацевтичен продукт